Key facts
- 52-week range (closes)
- $151.43 – $301.63 Lowest close Apr 10, 2026, highest Oct 13, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
- Fiscal year ends
- January Fiscal 2026 ended Jan 31, 2026, from SEC filings
- In the S&P 500 since
- May 7, 2026, replacing Coterra Energy (CTRA) · Devon Energy acquired Coterra Energy. · All S&P 500 changes
- Analyst coverage
- 7 open price targets from 6 firms: Stifel, Guggenheim, Needham, Oppenheimer, Piper Sandler, Wells Fargo Approved targets tracked here; see the analyst section below
Veeva Systems (VEEV) is trading up at $319.96 (+1.00%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on VEEV
Current price targets from 6 firms average $286, median $305, ranging from $225 to $330 — the average is 11% below the current $320. Each is tracked to its date and scored the same way a member's call is.
- Wells Fargo $265 → $330 by Sep 2027 Sep 8, 2026 via Investing.com · Wells Fargo's track record
- Piper Sandler $282 → $320 by Aug 2027 Aug 27, 2026 via Investing.com · Piper Sandler's track record
- Stifel $282 → $300 by Aug 2027 Aug 27, 2026 via Investing.com · Stifel's track record
- Needham $282 → $310 by Aug 2027 Aug 27, 2026 via Investing.com · Needham's track record
- Stifel $238 → $275 by Aug 2027 Aug 17, 2026 via Investing.com · Stifel's track record
- Guggenheim $185 → $232 by Jul 2027 Jul 22, 2026 via Investing.com · Guggenheim's track record
- Oppenheimer $197 → $225 by Jul 2027 Jul 20, 2026 via Investing.com · Oppenheimer's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Veeva Systems revenue & net income history (FY2017–FY2026)
| FY2017Jan 2017 | FY2018Jan 2018 | FY2019Jan 2019 | FY2020Jan 2020 | FY2021Jan 2021 | FY2022Jan 2022 | FY2023Jan 2023 | FY2024Jan 2024 | FY2025Jan 2025 | FY2026Jan 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $550.5M | $690.6M | $862.2M | $1.10B | $1.47B | $1.85B | $2.16B | $2.36B | $2.75B | $3.20B |
| Growth (year over year) | +34.5% | +25.4% | +24.9% | +28.1% | +32.7% | +26.3% | +16.4% | +9.7% | +16.2% | +16.3% |
| Gross profit | $376.9M | $479.1M | $616.9M | $800.7M | $1.06B | $1.35B | $1.55B | $1.69B | $2.05B | $2.41B |
| Gross margin | 68.5% | 69.4% | 71.6% | 72.5% | 72.1% | 72.8% | 71.7% | 71.3% | 74.5% | 75.5% |
| Operating income | $120.7M | $157.9M | $222.9M | $286.2M | $377.8M | $505.5M | $459.1M | $429.3M | $691.4M | $916.4M |
| Operating margin | 21.9% | 22.9% | 25.8% | 25.9% | 25.8% | 27.3% | 21.3% | 18.2% | 25.2% | 28.7% |
| Net income | $77.6M | $151.2M | $229.8M | $301.1M | $380.0M | $427.4M | $487.7M | $525.7M | $714.1M | $908.9M |
| Net margin | 14.1% | 21.9% | 26.7% | 27.3% | 25.9% | 23.1% | 22.6% | 22.2% | 26.0% | 28.4% |
| EPS (diluted) | $0.53 | $0.98 | $1.47 | $1.90 | $2.36 | $2.63 | $3.00 | $3.22 | $4.32 | $5.44 |
| Balance sheet | ||||||||||
| Cash and equivalents | $217.6M | $320.2M | $551.0M | $476.7M | $730.5M | $1.14B | $886.5M | $703.5M | $1.12B | $1.42B |
| Total assets | $917.4M | $1.23B | $1.65B | $2.27B | $3.05B | $3.82B | $4.80B | $5.91B | $7.34B | $8.98B |
| Total liabilities | $264.7M | $324.1M | $416.0M | $606.2M | $779.7M | $904.8M | $1.09B | $1.27B | $1.51B | $1.76B |
| Shareholders' equity | $678.2M | $906.2M | $1.24B | $1.67B | $2.27B | $2.91B | $3.72B | $4.64B | $5.83B | $7.21B |
| Cash flow | ||||||||||
| Operating cash flow | $144.0M | $233.4M | $310.8M | $437.4M | $551.2M | $764.5M | $780.5M | $911.3M | $1.09B | $1.42B |
| Capital expenditure | $6.92M | $9.63M | $8.44M | $3.11M | — | — | — | — | — | — |
| Free cash flow | $137.1M | $223.8M | $302.4M | $434.3M | — | — | — | — | — | — |
| Share buybacks | — | — | — | — | — | — | — | $0 | $0 | $169.9M |
| Q3 FY25Oct 2024 | Q4 FY25†Jan 2025 | Q1 FY26Apr 2025 | Q2 FY26Jul 2025 | Q3 FY26Oct 2025 | Q4 FY26†Jan 2026 | Q1 FY27Apr 2026 | Q2 FY27Jul 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $699.2M | $720.9M | $759.0M | $789.1M | $811.2M | $836.0M | $882.9M | $928.0M |
| Growth (year over year) | +13.4% | +14.3% | +16.7% | +16.7% | +16.0% | +16.0% | +16.3% | +17.6% |
| Gross profit | $524.8M | $539.9M | $585.2M | $593.8M | $611.8M | $622.5M | $662.0M | $696.0M |
| Gross margin | 75.1% | 74.9% | 77.1% | 75.3% | 75.4% | 74.5% | 75.0% | 75.0% |
| Operating income | $181.4M | $188.4M | $233.7M | $195.9M | $240.9M | $245.9M | $273.1M | $275.0M |
| Operating margin | 25.9% | 26.1% | 30.8% | 24.8% | 29.7% | 29.4% | 30.9% | 29.6% |
| Net income | $185.8M | $195.6M | $228.2M | $200.3M | $236.2M | $244.2M | $260.9M | $273.4M |
| Net margin | 26.6% | 27.1% | 30.1% | 25.4% | 29.1% | 29.2% | 29.6% | 29.5% |
| EPS (diluted) | $1.13 | $1.17 | $1.37 | $1.19 | $1.40 | $1.48 | $1.57 | $1.66 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.04B | $1.12B | $1.96B | $1.93B | $1.66B | $1.42B | $1.90B | $1.81B |
| Total assets | $6.45B | $7.34B | $7.77B | $8.00B | $8.10B | $8.98B | $9.13B | $9.06B |
| Total liabilities | $951.5M | $1.51B | $1.55B | $1.36B | $1.06B | $1.76B | $1.83B | $1.63B |
| Shareholders' equity | $5.50B | $5.83B | $6.21B | $6.64B | $7.04B | $7.21B | $7.30B | $7.43B |
| Cash flow | ||||||||
| Operating cash flow | $164.1M | $69.5M | $877.2M | $238.4M | $192.8M | $106.8M | $1.13B | $238.7M |
| Share buybacks | — | — | $0 | $0 | — | — | $226.9M | $245.7M |
From Veeva Systems's 10-K and 10-Q filings with the SEC; its fiscal year ends in January. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Veeva Systems vs the Health Care sector and the S&P 500
Veeva Systems's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.
| Measure | Veeva Systems | Health Care (59 other S&P 500 companies) | S&P 500 (502 other companies) |
|---|---|---|---|
| Revenue growth, latest fiscal year | +16.3% | +7.1% | +7.0% |
| Net margin, latest fiscal year | 28.4% | 12.9% | 12.9% |
| Share price change, 1 year | +10.8% | +19.8% | +5.6% |
Veeva Systems: fiscal year ended January 2026, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Veeva Systems included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them. The S&P 500 price figure is the middle company's change, not the index's return.
About Veeva Systems
Veeva Systems Inc., headquartered in Pleasanton, California, provides cloud computing software, data, and consulting services for the life sciences industry. Its products are used to track all aspects of drug development and pharmaceutical manufacturing.
Source: Wikipedia — Veeva Systems
- Headquarters
- Pleasanton, California From SEC filings, Oct 2026
Recent News (20)
-
Veeva to Host Virtual Investor Day on November 5, 2026 PLEASANTON, Calif., Oct. 14, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will host its investor day virtually on Thursday, November 5, 2026. The event will begin at 1:30 p.m. PT and will conclude …
-
Veeva Summit Platinum Sponsor Spotline to Showcase AI-Powered Validation Automation Live demonstrations of V-Assure AI and V-Assist will highlight validation automation and contextual user guidance within Veeva Vault BOSTON, Oct. 14, 2026 /PRNewswire/ -- Spotline Inc., a provider of …
-
IQVIA Selects Veeva Clinical Operations Applications RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif., Oct. 13, 2026 /PRNewswire/ -- IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) today announced an expansion of their partnership with the selection…
-
-
Veeva Summit to Showcase AI Innovations and the Leaders Transforming R&D and Quality Eli Lilly and Company, Pfizer, Sanofi, UCB, and more share learnings speeding drug development, connecting trials, and modernizing quality and manufacturing PLEASANTON, Calif., Oct. 8, 2026 /PRNewswir…
-
Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development More than 175 biotechs use pre-configured applications to streamline operations PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 175 emerging …
-
-
-
-
-
-
-
-
-
VEEV Stock Climbs As AI Vault CRM Momentum Fuels Target Hikes VEEV Stock Climbs As AI Vault CRM Momentum Fuels Target Hikes StocksToTrade
-
-
Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva With 190 live customers and 14 top 20 biopharma commitments, Vault CRM is the fastest path to AI PLEASANTON, Calif., Sept. 23, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a new top…
-
-
Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan TradingView
-
More Health Care stocks
- TECH Bio-Techne
- TMO Thermo Fisher Scientific
- UHS Universal Health Services
- UNH UnitedHealth Group
- VRTX Vertex Pharmaceuticals
- VTRS Viatris
- WAT Waters Corporation
- WST West Pharmaceutical Services